Last reviewed · How we verify
ONO-7436
At a glance
| Generic name | ONO-7436 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. (PHASE3)
- Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients (PHASE1)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (NA)
- Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) (PHASE4)
- Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (PHASE3)
- Comparison of Adding EMEND to PONV/PDNV Treatment Regimen (NA)
- An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-7436 CI brief — competitive landscape report
- ONO-7436 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI